Understanding Research Biosimilars

Research biosimilars play a crucial role in advancing scientific knowledge and medical innovation. They are products that are highly similar to an already approved biological reference product, offering researchers a cost-effective alternative for various experimental studies.

Research Biosimilars

View as Grid List

Items 49-60 of 387

per page
Set Descending Direction
  1. Enfortumab Biosimilar - Research Grade
    $300.00 - $5,000.00
  2. Briakinumab Biosimilar - Dylight®488 Research Grade
    $350.00
  3. Matuzumab Biosimilar - Research Grade
    $300.00 - $5,000.00
  4. Zagotenemab Biosimilar - Research Grade
    $300.00 - $5,000.00
  5. Magrolimab Biosimilar - Research Grade
    $300.00 - $5,000.00
  6. Obinutuzumab Biosimilar - Research Grade
    $300.00 - $5,000.00
  7. Alemtuzumab Biosimilar - Biotin Research Grade
    $350.00
  8. Ponezumab Biosimilar - Research Grade
    $300.00 - $5,000.00
  9. Camrelizumab Biosimilar - Research Grade
    $300.00 - $5,000.00
  10. Briakinumab Biosimilar - HRP Research Grade
    $350.00
  11. Nadunolimab Biosimilar - Research Grade
    $300.00 - $5,000.00
  12. Alemtuzumab Biosimilar - Dylight®488 Research Grade
    $350.00
View as Grid List

Items 49-60 of 387

per page
Set Descending Direction

How are Research Biosimilars Used?

Whether investigating the efficacy of immunotherapies, dissecting signaling pathways implicated in cancer progression, or unraveling the complexities of autoimmune diseases, research biosimilars serve as invaluable assets in the quest for scientific breakthroughs. Their ability to faithfully replicate the properties of reference biologics provides researchers with a reliable platform to conduct preclinical and translational research, ultimately paving the way for the development of innovative therapies and improving patient outcomes.

Featured Research Biosimilars

  • Peresolimab Biosimilar: Unlock the potential of immune checkpoint inhibitors with our Peresolimab Biosimilar, ideal for cancer immunotherapy research.
  • Amivantamab Biosimilar: Explore targeted therapy options for various solid tumors with our Amivantamab Biosimilar, designed for precision medicine research.
  • Cetuximab-GAALIE Biosimilar: Investigate novel treatment modalities for colorectal cancer and head and neck cancer with our Cetuximab-GAALIE Biosimilar, offering enhanced binding affinity for improved efficacy.
  • Teclistamab Biosimilar: Dive into the realm of bispecific antibodies with our Teclistamab Biosimilar, facilitating research in the fields of hematologic malignancies and solid tumors.
Back to Top